Developer docs
API playgroundTry for free, no card

Search company profiles

Lokon Pharma AB

Full company profile

uuid000e9x9

Namestring
Lokon Pharma AB
Legal namestring
Lokon Pharma AB
Websiteurl
lokonpharma.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Lokon Pharma AB is a privately held, clinical-stage Swedish biotechnology company headquartered in Uppsala and wholly owned by the venture capital firm nxt2b. The company develops the LOAd (Lokon Oncolytic Adenovirus) platform, a family of tumor microenvironment (TME) gene engineering vectors built on adenovirus serotype 5/35 that encode immunostimulatory transgenes designed to convert immunosuppressive tumor stroma into an immune-activated state. The lead asset LOAd703 is a double-armed virus encoding TMZ-CD40L and 4-1BBL, making Lokon the first company to test more than one immunostimulatory gene in humans via an oncolytic virus.

LOAd703 has been evaluated in three Phase I/II trials — LOKON001 (pancreatic cancer, US), LOKON002 (pancreatic, ovarian, biliary, and colorectal cancer, Sweden), and LOKON003 (malignant melanoma, Sweden and US) — with results published in Lancet Oncology (March 2024) and Nature Communications (February 2026). The asset carries FDA Orphan Drug Designation and EMA Orphan Drug Designation (both 2015) and received FDA Fast Track Designation in January 2025. The pipeline also includes LOAd732 (triple-armed, preclinical), LOAd713, and Ad825. The company has established clinical collaborations with Roche (since 2019, expanded 2020 into colorectal cancer), BeiGene (November 2024, tislelizumab combination), Affibody (January 2022), and City of Hope (May 2023).

Lokon operates as a pre-revenue company with no product sales; distribution of its investigational therapies occurs exclusively through clinical trial sites in Sweden and the US. The company is funded by parent nxt2b and has not disclosed external funding rounds or licensing economics. Its GTM motion centers on scientific engagement (AACR, ESMO, ASCO, CIMT presentations), peer-reviewed publication, and strategic pharma partnerships intended to support future commercialization. Headcount is reported at 1-10 employees.

Short descriptiontext

Lokon Pharma AB is a pre-revenue, Uppsala-based Swedish clinical-stage biotech developing the LOAd oncolytic adenovirus platform (lead asset LOAd703) for solid tumors including pancreatic, ovarian, colorectal, biliary, and melanoma cancers, delivered via clinical trials and partnered with Roche and BeiGene.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncolytic virus therapy, cancer immunotherapy, tumor microenvironment engineering, oncolytic adenovirus platform, clinical stage biotech
Industry3 codes
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncolytic Virus Immunotherapy
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Biopharmaceutical Development
TypeLicensing Royalties
Description

As a pre-revenue clinical-stage biotech company, Lokon Pharma does not currently generate product revenue. The company is wholly owned by nxt2b, a Swedish venture capital firm specializing in healthcare investments. Development is funded through VC investment and potential future licensing deals or acquisitions.

lokonpharma.com
2Future Product Commercialization
TypeOne Time License
Description

Upon regulatory approval, the company would commercialize LOAd therapy products, likely through partnership with larger pharmaceutical companies for global distribution, or through direct commercialization in select markets.

lokonpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1LOAd
Description

LOAd (Lightning Oncolytic Adenovirus) is a family of tumor microenvironment (TME) gene engineering vectors based on oncolytic adenoviruses. The LOAd family includes LOAd703 (clinical stage) and LOAd732 (preclinical), which encode different immunostimulatory genes for cancer treatment.

lokonpharma.com
Core offering1 text field

Lokon Pharma develops a proprietary family of tumor microenvironment (TME) gene engineering vectors called LOAd (Lightning Oncolytic Adenovirus), built on adenovirus serotype 5/35 backbones engineered to encode immunostimulatory transgenes. Its lead product LOAd703 is a double-armed oncolytic adenovirus carrying TMZ-CD40L and 4-1BBL, currently in Phase I/II clinical trials for pancreatic cancer, ovarian cancer, colorectal cancer, biliary cancer, and melanoma. The company also develops pipeline variants LOAd732, LOAd713, and Ad825, and combines its vectors with chemotherapy and checkpoint inhibitors through partnerships with Roche, BeiGene, and Affibody.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase I/II pancreatic cancer trial results published in Lancet Oncology (March 2024)
+1 more record
Product overview1 text field

Lokon Pharma AB is a Swedish biotech company developing the LOAd (Lokon Oncolytic Adenovirus) technology platform, a family of tumor microenvironment (TME) gene engineering vectors based on oncolytic adenoviruses. The core product LOAd703 is a double-armed oncolytic virus encoding immunostimulatory genes TMZ-CD40L and 4-1BBL. The company is advancing multiple clinical trials (LOKON001, LOKON002, LOKON003) in pancreatic, ovarian, colorectal, biliary cancers and melanoma. The LOAd pipeline also includes LOAd732 (triple-armed), LOAd713, and Ad825 vectors at various development stages. These gene therapy products are administered via intratumoral injection and work by both direct tumor cell killing (oncolysis) and activation of anti-tumor immune responses.

Product and service4 records
1LOAd703
CategoryClinical-stage oncolytic virus immunotherapy product
Description

Double-armed oncolytic adenovirus (adenovirus serotype 5/35) encoding two immunostimulatory transgenes (TMZ-CD40L and 4-1BBL). Lead clinical-stage product administered via intratumoral injection; induces tumor stroma inflammation, activates dendritic cells and M1 macrophages, drives Th1 cytokine production, and expands NK cells and memory T cells. In Phase I/II trials for pancreatic, ovarian, colorectal, biliary cancer, and malignant melanoma. Has received FDA Fast Track Designation (2025) and EMA and FDA Orphan Drug Designations (2015).

2LOAd732
CategoryPipeline oncolytic virus immunotherapy product
Description

Triple-armed oncolytic adenovirus variant in the LOAd virus family; preclinical-stage candidate being evaluated for mechanisms-of-action and proof-of-concept as the next-generation evolution of the LOAd platform.

3LOAd713
CategoryPipeline oncolytic virus immunotherapy product
Description

Oncolytic adenovirus variant in the LOAd virus family; published data in the Journal of Immunology (2019) supporting its role within the broader LOAd platform.

4Ad825
CategoryPipeline oncolytic virus immunotherapy product
Description

Preclinical tumor microenvironment gene engineering vector in the LOAd virus family; presented by PhD student Anja Ritter at CIMT 2026 with research focused on soft-tissue sarcoma targeting and on CD40/4-1BB/PD-L1 immunostimulatory gene combinations.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-04
Description

Collaboration to combine Lokon's TME gene engineering product (LOAd703) with BeiGene's anti-PD-1 antibody tislelizumab in pancreatic cancer treatment.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-05-19
Description

Collaboration project using neural stem cells as cell delivery vehicles for Lokon's LOAd703. Presented at American Society for Gene and Cell Therapy (ASGCT) conference in Los Angeles.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-12
Description

Collaboration initiated to develop novel cancer therapeutics combining Affibody's technology with Lokon's LOAd platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-28
Description

Collaboration expanded to evaluate LOAd703 immunostimulatory gene cancer therapy in combination with Tecentriq (atezolizumab) in colorectal cancer. Previously combined with atezolizumab in melanoma and pancreatic cancer. Roche collaboration began in 2019.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-06-03
Description

Initial collaboration to combine LOAd703 oncolytic virotherapy with checkpoint blockade in pancreatic cancer and melanoma. Led to expanded collaboration in 2020.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1PsiOxus Therapeutics (Akamis Bio)
TypeDirect peer
Description

Clinical-stage biotech developing oncolytic virus platform (enadenotucirev and NG-641) for solid tumors, with combination trials in checkpoint inhibitor settings. Direct peer in OV class, clinical stage, and combination focus.

TypeDirect peer
Description

Clinical-stage biotech developing oncolytic virus therapies (Voyager-V1 and related vesicular stomatitis virus platforms) for solid tumors with combination trial strategies. Direct peer in OV technology and clinical-stage positioning.

TypeEmerging player
Description

Biotech company with a broader portfolio spanning cell therapies, antibodies, and oncolytic virus approaches. Less direct alignment than the pure-play OV peers, but overlapping in cancer immunotherapy development and combination strategies.

TypeDirect peer
Description

Clinical-stage biotech developing oncolytic viral immunotherapies (CAN-2409, CAN-3110) for solid tumors including pancreatic cancer and high-grade glioma. Direct peer in OV technology class with overlapping lead indication (pancreatic cancer).

TypeDirect peer
Description

Clinical-stage biotech developing a portfolio of oncolytic virus therapies (RP1, RP2, RP3) based on a proprietary engineered HSV-1 platform, with multiple combination trials including checkpoint inhibitors. Directly comparable to Lokon in technology class (oncolytic virotherapy), clinical stage, and combination strategy.

6Oncorus
TypeDirect peer
Description

Clinical-stage biotech developing oncolytic virus therapies (intratumoral and intravenous approaches) including ONCR-177 and an HSV platform. Direct peer in OV technology class and clinical-stage development for solid tumors.

7Targovax
TypeDirect peer
Description

Norwegian clinical-stage biotech developing oncolytic virus platform (ONCOS-102) in mesothelioma and other solid tumors, with checkpoint inhibitor combinations. Direct European peer in the OV class with similar clinical-stage positioning and combination strategy.

8Turnstone Biologics
TypeDirect peer
Description

Clinical-stage biotech developing oncolytic virus immunotherapies (TBio-4101 and TIDAL platform) for solid tumors. Direct peer in OV technology class with overlapping clinical-stage development for solid tumor indications.

TypeBroad incumbent
Description

Major pharmaceutical company that markets Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy for melanoma. Represents the commercial validation and incumbent positioning in the OV class that Lokon is targeting, and the standard against which any new OV entrant will be benchmarked commercially.

TypeDirect peer
Description

Clinical-stage biotech developing oncolytic vaccinia virus platform (Olvi-Vec) for solid tumors including ovarian cancer. Direct peer in OV technology class with overlapping clinical-stage positioning in solid tumor oncology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lokon Pharma AB

Oncolytic Virus Immunotherapylokonpharma.com

Lokon Pharma AB is a pre-revenue, Uppsala-based Swedish clinical-stage biotech developing the LOAd oncolytic adenovirus platform (lead asset LOAd703) for solid tumors including pancreatic, ovarian, colorectal, biliary, and melanoma cancers, delivered via clinical trials and partnered with Roche and BeiGene.

What Lokon Pharma AB does

Lokon Pharma AB is a privately held, clinical-stage Swedish biotechnology company headquartered in Uppsala and wholly owned by the venture capital firm nxt2b. The company develops the LOAd (Lokon Oncolytic Adenovirus) platform, a family of tumor microenvironment (TME) gene engineering vectors built on adenovirus serotype 5/35 that encode immunostimulatory transgenes designed to convert immunosuppressive tumor stroma into an immune-activated state. The lead asset LOAd703 is a double-armed virus encoding TMZ-CD40L and 4-1BBL, making Lokon the first company to test more than one immunostimulatory gene in humans via an oncolytic virus.

LOAd703 has been evaluated in three Phase I/II trials — LOKON001 (pancreatic cancer, US), LOKON002 (pancreatic, ovarian, biliary, and colorectal cancer, Sweden), and LOKON003 (malignant melanoma, Sweden and US) — with results published in Lancet Oncology (March 2024) and Nature Communications (February 2026). The asset carries FDA Orphan Drug Designation and EMA Orphan Drug Designation (both 2015) and received FDA Fast Track Designation in January 2025. The pipeline also includes LOAd732 (triple-armed, preclinical), LOAd713, and Ad825. The company has established clinical collaborations with Roche (since 2019, expanded 2020 into colorectal cancer), BeiGene (November 2024, tislelizumab combination), Affibody (January 2022), and City of Hope (May 2023).

Lokon operates as a pre-revenue company with no product sales; distribution of its investigational therapies occurs exclusively through clinical trial sites in Sweden and the US. The company is funded by parent nxt2b and has not disclosed external funding rounds or licensing economics. Its GTM motion centers on scientific engagement (AACR, ESMO, ASCO, CIMT presentations), peer-reviewed publication, and strategic pharma partnerships intended to support future commercialization. Headcount is reported at 1-10 employees.

Lokon Pharma AB firmographics

Firmographics
Name
Lokon Pharma AB
Legal name
Lokon Pharma AB
Website
https://lokonpharma.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
1–10 employees
Short description
Lokon Pharma AB is a pre-revenue, Uppsala-based Swedish clinical-stage biotech developing the LOAd oncolytic adenovirus platform (lead asset LOAd703) for solid tumors including pancreatic, ovarian, colorectal, biliary, and melanoma cancers, delivered via clinical trials and partnered with Roche and BeiGene.
Ownership category
akta.pro rank

Lokon Pharma AB industry classification

Industry
Product category
Oncolytic Virus Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oncolytic virus therapy
  • Cancer immunotherapy
  • Tumor microenvironment engineering
  • Oncolytic adenovirus platform
  • Clinical stage biotech

Where Lokon Pharma AB is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Lokon Pharma AB business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Biopharmaceutical Development: As a pre-revenue clinical-stage biotech company, Lokon Pharma does not currently generate product revenue. The company is wholly owned by nxt2b, a Swedish venture capital firm specializing in healthcare investments. Development is funded through VC investment and potential future licensing deals or acquisitions.
  2. Future Product Commercialization: Upon regulatory approval, the company would commercialize LOAd therapy products, likely through partnership with larger pharmaceutical companies for global distribution, or through direct commercialization in select markets.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Lokon Pharma AB product offering

Product offering

Core offering

Lokon Pharma develops a proprietary family of tumor microenvironment (TME) gene engineering vectors called LOAd (Lightning Oncolytic Adenovirus), built on adenovirus serotype 5/35 backbones engineered to encode immunostimulatory transgenes. Its lead product LOAd703 is a double-armed oncolytic adenovirus carrying TMZ-CD40L and 4-1BBL, currently in Phase I/II clinical trials for pancreatic cancer, ovarian cancer, colorectal cancer, biliary cancer, and melanoma. The company also develops pipeline variants LOAd732, LOAd713, and Ad825, and combines its vectors with chemotherapy and checkpoint inhibitors through partnerships with Roche, BeiGene, and Affibody.

Product overview

Lokon Pharma AB is a Swedish biotech company developing the LOAd (Lokon Oncolytic Adenovirus) technology platform, a family of tumor microenvironment (TME) gene engineering vectors based on oncolytic adenoviruses. The core product LOAd703 is a double-armed oncolytic virus encoding immunostimulatory genes TMZ-CD40L and 4-1BBL. The company is advancing multiple clinical trials (LOKON001, LOKON002, LOKON003) in pancreatic, ovarian, colorectal, biliary cancers and melanoma. The LOAd pipeline also includes LOAd732 (triple-armed), LOAd713, and Ad825 vectors at various development stages. These gene therapy products are administered via intratumoral injection and work by both direct tumor cell killing (oncolysis) and activation of anti-tumor immune responses.

Differentiator

Problem solved

Functional benefit

Brands

  • LOAd: LOAd (Lightning Oncolytic Adenovirus) is a family of tumor microenvironment (TME) gene engineering vectors based on oncolytic adenoviruses. The LOAd family includes LOAd703 (clinical stage) and LOAd732 (preclinical), which encode different immunostimulatory genes for cancer treatment.

Products and services

  • LOAd703 Double-armed oncolytic adenovirus (adenovirus serotype 5/35) encoding two immunostimulatory transgenes (TMZ-CD40L and 4-1BBL). Lead clinical-stage product administered via intratumoral injection; induces tumor stroma inflammation, activates dendritic cells and M1 macrophages, drives Th1 cytokine production, and expands NK cells and memory T cells. In Phase I/II trials for pancreatic, ovarian, colorectal, biliary cancer, and malignant melanoma. Has received FDA Fast Track Designation (2025) and EMA and FDA Orphan Drug Designations (2015).
  • LOAd732 Triple-armed oncolytic adenovirus variant in the LOAd virus family; preclinical-stage candidate being evaluated for mechanisms-of-action and proof-of-concept as the next-generation evolution of the LOAd platform.
  • LOAd713 Oncolytic adenovirus variant in the LOAd virus family; published data in the Journal of Immunology (2019) supporting its role within the broader LOAd platform.
  • Ad825 Preclinical tumor microenvironment gene engineering vector in the LOAd virus family; presented by PhD student Anja Ritter at CIMT 2026 with research focused on soft-tissue sarcoma targeting and on CD40/4-1BB/PD-L1 immunostimulatory gene combinations.

Quantifiable outcome

  • Phase I/II pancreatic cancer trial results published in Lancet Oncology (March 2024)
  • +1 more outcomes

Companies that use Lokon Pharma AB

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Lokon Pharma AB technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Lokon Pharma AB partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • BeiGenecoreStrategic or Co-development Partner · 4 November 2024Collaboration to combine Lokon's TME gene engineering product (LOAd703) with BeiGene's anti-PD-1 antibody tislelizumab in pancreatic cancer treatment.
  • City of HopeminorStrategic or Co-development Partner · 19 May 2023Collaboration project using neural stem cells as cell delivery vehicles for Lokon's LOAd703. Presented at American Society for Gene and Cell Therapy (ASGCT) conference in Los Angeles.
  • AffibodyminorStrategic or Co-development Partner · 12 January 2022Collaboration initiated to develop novel cancer therapeutics combining Affibody's technology with Lokon's LOAd platform.
  • RochecoreStrategic or Co-development Partner · 28 August 2020Collaboration expanded to evaluate LOAd703 immunostimulatory gene cancer therapy in combination with Tecentriq (atezolizumab) in colorectal cancer. Previously combined with atezolizumab in melanoma and pancreatic cancer. Roche collaboration began in 2019.
  • Roche (initial)coreStrategic or Co-development Partner · 3 June 2019Initial collaboration to combine LOAd703 oncolytic virotherapy with checkpoint blockade in pancreatic cancer and melanoma. Led to expanded collaboration in 2020.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Lokon Pharma AB competitors and assessment

Company assessment

Direct peers

  • PsiOxus Therapeutics (Akamis Bio): Clinical-stage biotech developing oncolytic virus platform (enadenotucirev and NG-641) for solid tumors, with combination trials in checkpoint inhibitor settings. Direct peer in OV class, clinical stage, and combination focus.
  • Vyriad: Clinical-stage biotech developing oncolytic virus therapies (Voyager-V1 and related vesicular stomatitis virus platforms) for solid tumors with combination trial strategies. Direct peer in OV technology and clinical-stage positioning.
  • Candel Therapeutics: Clinical-stage biotech developing oncolytic viral immunotherapies (CAN-2409, CAN-3110) for solid tumors including pancreatic cancer and high-grade glioma. Direct peer in OV technology class with overlapping lead indication (pancreatic cancer).
  • Replimune Group: Clinical-stage biotech developing a portfolio of oncolytic virus therapies (RP1, RP2, RP3) based on a proprietary engineered HSV-1 platform, with multiple combination trials including checkpoint inhibitors. Directly comparable to Lokon in technology class (oncolytic virotherapy), clinical stage, and combination strategy.
  • Oncorus: Clinical-stage biotech developing oncolytic virus therapies (intratumoral and intravenous approaches) including ONCR-177 and an HSV platform. Direct peer in OV technology class and clinical-stage development for solid tumors.
  • Targovax: Norwegian clinical-stage biotech developing oncolytic virus platform (ONCOS-102) in mesothelioma and other solid tumors, with checkpoint inhibitor combinations. Direct European peer in the OV class with similar clinical-stage positioning and combination strategy.
  • Turnstone Biologics: Clinical-stage biotech developing oncolytic virus immunotherapies (TBio-4101 and TIDAL platform) for solid tumors. Direct peer in OV technology class with overlapping clinical-stage development for solid tumor indications.
  • Genelux Corporation: Clinical-stage biotech developing oncolytic vaccinia virus platform (Olvi-Vec) for solid tumors including ovarian cancer. Direct peer in OV technology class with overlapping clinical-stage positioning in solid tumor oncology.

Emerging players

  • Sorrento Therapeutics: Biotech company with a broader portfolio spanning cell therapies, antibodies, and oncolytic virus approaches. Less direct alignment than the pure-play OV peers, but overlapping in cancer immunotherapy development and combination strategies.

Broad incumbents

  • Amgen (Imlygic / T-VEC): Major pharmaceutical company that markets Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy for melanoma. Represents the commercial validation and incumbent positioning in the OV class that Lokon is targeting, and the standard against which any new OV entrant will be benchmarked commercially.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Lokon Pharma AB social profiles

Digital presence

Lokon Pharma AB compliance and trust

Trust signal

Compliance3 records

Lokon Pharma AB financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lokon Pharma AB leadership team

Management profile

Number of profiles

Profiles8 records

Lokon Pharma AB funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lokon Pharma AB M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lokon Pharma AB

What does Lokon Pharma AB do?

Lokon Pharma develops a proprietary family of tumor microenvironment (TME) gene engineering vectors called LOAd (Lightning Oncolytic Adenovirus), built on adenovirus serotype 5/35 backbones engineered to encode immunostimulatory transgenes. Its lead product LOAd703 is a double-armed oncolytic adenovirus carrying TMZ-CD40L and 4-1BBL, currently in Phase I/II clinical trials for pancreatic cancer, ovarian cancer, colorectal cancer, biliary cancer, and melanoma. The company also develops pipeline variants LOAd732, LOAd713, and Ad825, and combines its vectors with chemotherapy and checkpoint inhibitors through partnerships with Roche, BeiGene, and Affibody.

Is Lokon Pharma AB a public or private company?

Lokon Pharma AB is a private company. It is classified as venture growth investor backed and is currently operating.

When was Lokon Pharma AB founded?

Lokon Pharma AB was founded in 1999. It employs 1 to 10 people.

Where is Lokon Pharma AB based?

Lokon Pharma AB is headquartered in Uppsala, Sweden, in the Europe region.

How does Lokon Pharma AB make money?

Two revenue lines are on record. Biopharmaceutical Development is the primary driver. The others are future Product Commercialization.

Who are Lokon Pharma AB's main competitors?

Direct peers on record are PsiOxus Therapeutics (Akamis Bio), Vyriad, Candel Therapeutics, Replimune Group, Oncorus, Targovax, Turnstone Biologics and Genelux Corporation. Sorrento Therapeutics is listed as an emerging player. Amgen (Imlygic / T-VEC) is listed as a broad incumbent.

Does Lokon Pharma AB have an API?

No public API is recorded for Lokon Pharma AB.

What industry is Lokon Pharma AB in?

Lokon Pharma AB's product category is Oncolytic Virus Immunotherapy. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream), with a secondary code of HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals